| Title: | First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitis |
|---|
| Authors: | ID Supovec, Eva (Author)
ID Hanžel, Jurij (Author)
ID Novak, Gregor (Author)
ID Manevski, Damjan (Author)
ID Štabuc, Borut (Author)
ID Drobne, David (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,04 MB)
MD5: 14705A3FAAC88426C8B2F1228AAD8B52
 URL - Source URL, visit https://journals.lww.com/eurojgh/fulltext/2025/05000/first_line_anti_tnf_agents,_ustekinumab_and.5.aspx
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Background: Real-word comparisons between first-line biologicals in inflammatory bowel disease (IBD) are scarce. Aims: The aim of this study is to compare drug persistence and patient reported outcome-2 (PRO-2) remission rates of first-line biological classes [anti-tumor necrosis factor (TNF) agents vs anti-integrin vedolizumab vs IL-12/23 inhibitor ustekinumab] in real life cohort. Methods: Individual level data of 946 adults (588 Crohn's disease and 358 ulcerative colitis) were retrieved from UR-CARE IBD platform. Adjusted drug survival curves using a pooled logistic model and PRO-2 remission rates for each class of biologicals were calculated and compared. Results: In Crohn's disease, no differences in drug survival were observed for anti-TNF agents vs vedolizumab vs ustekinumab as estimated survival with 95% confidence intervals were 0.81 (0.77-0.84) vs 0.89 (0.82-0.96) vs 0.88 (0.79-0.97) at year 1 and 0.52 (0.46-0.58) vs 0.58 (0.37-0.78) vs 0.58 (0.39-0.77) at year 4. In ulcerative colitis, however, anti-TNF agents had shorter drug survival than vedolizumab with estimated drug survival with 95% confidence intervals 0.60 (0.52-0.67) vs 0.76 (0.67-0.84) at year 1 and 0.37 (0.30-0.44) vs 0.50 (0.36-0.64) at year 4. No differences in PRO-2 remission rates were observed between drug classes in Crohn's disease (P = 0.95), but more patients enjoyed PRO-2 remission in ulcerative colitis treated with anti-TNF agents compared to vedolizumab (94.8 vs 78.9%, P = 0.002). Conclusion: Our real-world data suggest similar drug persistence and efficacy of first-line treatments with anti-TNF agents, vedolizumab and ustekinumab in Crohn's disease. In ulcerative colitis, however, drug persistence was higher for vedolizumab compared to anti-TNF agents, but on the cost of lower PRO-2 remission rates. |
|---|
| Keywords: | anti-TNF agents, ustekinumab, vedolizumab |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2025 |
|---|
| Number of pages: | str. 557-564 |
|---|
| Numbering: | Vol. 37, no. 5 |
|---|
| PID: | 20.500.12556/DiRROS-24481  |
|---|
| UDC: | 61 |
|---|
| ISSN on article: | 1473-5687 |
|---|
| DOI: | 10.1097/MEG.0000000000002940 |
|---|
| COBISS.SI-ID: | 226849539 |
|---|
| Copyright: | V članku navedeno Copyright © 2025 The Author(s). Na pristajalni strani članka je navedena licenca: Creative Commons CC-BY-NC-ND. |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 20. 2. 2025;
|
|---|
| Publication date in DiRROS: | 01.12.2025 |
|---|
| Views: | 79 |
|---|
| Downloads: | 43 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
